Stoke Therapeutics Inc. Insider Trading

STOK

Last 12 months

Insiders sold $8.98M and bought nothing on the open market.

83% of the selling was scheduled in advance under 10b5-1 plans. General Counsel & Corp Sec Jonathan Allan sold 286K on Mar 18, 24% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2020.

Net open-market

−$8.98M

0 buys · 32 sales

Under a 10b5-1 plan

83%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Nov 2020

Nov 24, 2020

Get an email when STOK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 2	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 2 parts	7,195	$26.39 average	190K	38%	Form 4
Oct 2	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan	627	$26.33	17K	3.0%	Form 4
Oct 1	Barry Ticho Chief Medical Officer	Sold10b5-1 plan	1,051	$26.16	27K	5.2%	Form 4
Sep 1	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 2 parts	5,545	$30.67 average	170K	22%	Form 4
Aug 18	Jonathan Allan General Counsel & Corp Sec	SoldNo plan 2 parts	2,861	$32.03 average	92K	12%	Form 4
Aug 18	Barry Ticho Chief Medical Officer	SoldNo plan 2 parts	4,767	$32.03 average	153K	16%	Form 4
Aug 18	Edward M. Md Kaye Director	SoldNo plan 2 parts	12,567	$32.03 average	403K	9.2%	Form 4
Aug 3	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 2 parts	7,176	$29.04 average	208K	26%	Form 4
Jul 1	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 2 parts	7,228	$32.66 average	236K	21%	Form 4
Jun 16	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan	1,457	$29.95	44K	7.5%	Form 4
Jun 1	Barry Ticho Chief Medical Officer	Sold10b5-1 plan	1,795	$30.58	55K	4.9%	Form 4
May 1	Barry Ticho Chief Medical Officer	Sold10b5-1 plan	2,243	$32.79	74K	5.8%	Form 4
Apr 1	Barry Ticho Chief Medical Officer	Sold10b5-1 plan	1,838	$32.66	60K	4.5%	Form 4
Mar 20	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan 2 parts	9,293	$33.69 average	313K	32%	Form 4
Mar 17 – 19	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 6 parts	14,311	$31.92 average	457K	26%	Form 4
Mar 17 – 18	Jonathan Allan General Counsel & Corp Sec	SoldNo plan 5 parts	8,895	$32.14 average	286K	24%	Form 4
Mar 17 – 18	Thomas Leggett Chief Financial Officer	SoldNo plan 5 parts	4,578	$32.14 average	147K	31%	Form 4
Mar 17 – 18	Jason Hoitt Chief Patient Officer	SoldNo plan 5 parts	3,712	$32.14 average	119K	27%	Form 4
Mar 13	Arthur A Levin Director	Sold10b5-1 plan	605	$36.80	22K	2.7%	Form 4
Mar 10	Adrian R. Krainer Director	Sold10b5-1 plan	33,243	$39.74	$1.32M	11%	Form 4
Mar 10	Arthur Tzianabos Interim Executive Chair	Sold10b5-1 plan	4,355	$40.00	174K	12%	Form 4
Mar 2	Adrian R. Krainer Director	Sold10b5-1 plan	7,229	$39.66	287K	2.2%	Form 4
Dec 8, 2025	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan 2 parts	3,978	$32.28 average	128K	25%	Form 4
Dec 8, 2025	Edward M. Md Kaye Director	Sold10b5-1 plan 3 parts	13,430	$32.27 average	433K	21%	Form 4
Dec 4, 2025 – Dec 5, 2025	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan 5 parts	9,803	$31.25 average	306K	38%	Form 4
Dec 4, 2025 – Dec 5, 2025	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 4 parts	5,358	$31.19 average	167K	21%	Form 4
Dec 4, 2025 – Dec 5, 2025	Edward M. Md Kaye Director	Sold10b5-1 plan 5 parts	15,001	$31.13 average	467K	19%	Form 4
Dec 2, 2025 – Dec 3, 2025	Jonathan Allan General Counsel & Corp Sec	SoldNo plan 4 parts	4,576	$30.22 average	138K	19%	Form 4
Dec 2, 2025 – Dec 3, 2025	Barry Ticho Chief Medical Officer	SoldNo plan 4 parts	4,020	$30.22 average	121K	21%	Form 4
Dec 2, 2025 – Dec 3, 2025	Edward M. Md Kaye Director	SoldNo plan 4 parts	2,136	$30.22 average	65K	4.0%	Form 4
Nov 24, 2025	Adrian R. Krainer Director	Sold10b5-1 plan	40,472	$29.72	$1.2M	11%	Form 4
Nov 14, 2025	Adrian R. Krainer Director	Sold10b5-1 plan 2 parts	40,472	$26.98 average	$1.09M	10%	Form 4
Nov 3, 2025	Barry Ticho Chief Medical Officer	Sold10b5-1 plan 4 parts	5,931	$25.72 average	153K	45%	Form 4
Oct 8, 2025	Edward M. Md Kaye Director	Sold10b5-1 plan	25,000	$30.00	750K	34%	Form 4
Oct 3, 2025	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan	10,000	$25.07	251K	46%	Form 4
Oct 3, 2025	Edward M. Md Kaye Director	Sold10b5-1 plan	42,461	$25.09	$1.07M	46%	Form 4
Oct 1, 2025	Barry Ticho Chief Medical Officer	Sold10b5-1 plan	5,343	$23.64	126K	29%	Form 4
Aug 29, 2025 – Sep 3, 2025	Edward M. Md Kaye Director	Sold10b5-1 plan 3 parts	61,885	$20.13 average	$1.25M	40%	Form 4
Aug 29, 2025 – Sep 3, 2025	Jonathan Allan General Counsel & Corp Sec	Sold10b5-1 plan 3 parts	22,117	$20.11 average	445K	65%	Form 4
Sep 2, 2025	Barry Ticho Chief Medical Officer	Sold10b5-1 plan	5,501	$19.87	109K	23%	Form 4

Nov 210b5-1 plan
Barry Ticho
Chief Medical Officer · sold 7,195 at avg $26.39
190K
38% of stake
Oct 210b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 627 at $26.33
17K
3.0% of stake
Oct 110b5-1 plan
Barry Ticho
Chief Medical Officer · sold 1,051 at $26.16
27K
5.2% of stake
Sep 110b5-1 plan
Barry Ticho
Chief Medical Officer · sold 5,545 at avg $30.67
170K
22% of stake
Aug 18No plan
Jonathan Allan
General Counsel & Corp Sec · sold 2,861 at avg $32.03
92K
12% of stake
Aug 18No plan
Barry Ticho
Chief Medical Officer · sold 4,767 at avg $32.03
153K
16% of stake
Aug 18No plan
Edward M. Md Kaye
Director · sold 12,567 at avg $32.03
403K
9.2% of stake
Aug 310b5-1 plan
Barry Ticho
Chief Medical Officer · sold 7,176 at avg $29.04
208K
26% of stake
Jul 110b5-1 plan
Barry Ticho
Chief Medical Officer · sold 7,228 at avg $32.66
236K
21% of stake
Jun 1610b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 1,457 at $29.95
44K
7.5% of stake
Jun 110b5-1 plan
Barry Ticho
Chief Medical Officer · sold 1,795 at $30.58
55K
4.9% of stake
May 110b5-1 plan
Barry Ticho
Chief Medical Officer · sold 2,243 at $32.79
74K
5.8% of stake
Apr 110b5-1 plan
Barry Ticho
Chief Medical Officer · sold 1,838 at $32.66
60K
4.5% of stake
Mar 2010b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 9,293 at avg $33.69
313K
32% of stake
Mar 17 – 1910b5-1 plan
Barry Ticho
Chief Medical Officer · sold 14,311 at avg $31.92
457K
26% of stake
Mar 17 – 18No plan
Jonathan Allan
General Counsel & Corp Sec · sold 8,895 at avg $32.14
286K
24% of stake
Mar 17 – 18No plan
Thomas Leggett
Chief Financial Officer · sold 4,578 at avg $32.14
147K
31% of stake
Mar 17 – 18No plan
Jason Hoitt
Chief Patient Officer · sold 3,712 at avg $32.14
119K
27% of stake
Mar 1310b5-1 plan
Arthur A Levin
Director · sold 605 at $36.80
22K
2.7% of stake
Mar 1010b5-1 plan
Adrian R. Krainer
Director · sold 33,243 at $39.74
$1.32M
11% of stake
Mar 1010b5-1 plan
Arthur Tzianabos
Interim Executive Chair · sold 4,355 at $40.00
174K
12% of stake
Mar 210b5-1 plan
Adrian R. Krainer
Director · sold 7,229 at $39.66
287K
2.2% of stake
Dec 8, 202510b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 3,978 at avg $32.28
128K
25% of stake
Dec 8, 202510b5-1 plan
Edward M. Md Kaye
Director · sold 13,430 at avg $32.27
433K
21% of stake
Dec 4, 2025 – Dec 5, 202510b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 9,803 at avg $31.25
306K
38% of stake
Dec 4, 2025 – Dec 5, 202510b5-1 plan
Barry Ticho
Chief Medical Officer · sold 5,358 at avg $31.19
167K
21% of stake
Dec 4, 2025 – Dec 5, 202510b5-1 plan
Edward M. Md Kaye
Director · sold 15,001 at avg $31.13
467K
19% of stake
Dec 2, 2025 – Dec 3, 2025No plan
Jonathan Allan
General Counsel & Corp Sec · sold 4,576 at avg $30.22
138K
19% of stake
Dec 2, 2025 – Dec 3, 2025No plan
Barry Ticho
Chief Medical Officer · sold 4,020 at avg $30.22
121K
21% of stake
Dec 2, 2025 – Dec 3, 2025No plan
Edward M. Md Kaye
Director · sold 2,136 at avg $30.22
65K
4.0% of stake
Nov 24, 202510b5-1 plan
Adrian R. Krainer
Director · sold 40,472 at $29.72
$1.2M
11% of stake
Nov 14, 202510b5-1 plan
Adrian R. Krainer
Director · sold 40,472 at avg $26.98
$1.09M
10% of stake
Nov 3, 202510b5-1 plan
Barry Ticho
Chief Medical Officer · sold 5,931 at avg $25.72
153K
45% of stake
Oct 8, 202510b5-1 plan
Edward M. Md Kaye
Director · sold 25,000 at $30.00
750K
34% of stake
Oct 3, 202510b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 10,000 at $25.07
251K
46% of stake
Oct 3, 202510b5-1 plan
Edward M. Md Kaye
Director · sold 42,461 at $25.09
$1.07M
46% of stake
Oct 1, 202510b5-1 plan
Barry Ticho
Chief Medical Officer · sold 5,343 at $23.64
126K
29% of stake
Aug 29, 2025 – Sep 3, 202510b5-1 plan
Edward M. Md Kaye
Director · sold 61,885 at avg $20.13
$1.25M
40% of stake
Aug 29, 2025 – Sep 3, 202510b5-1 plan
Jonathan Allan
General Counsel & Corp Sec · sold 22,117 at avg $20.11
445K
65% of stake
Sep 2, 202510b5-1 plan
Barry Ticho
Chief Medical Officer · sold 5,501 at $19.87
109K
23% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch STOK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with STOK

CompareIntrinsic value

JAGXJaguar Health, Inc.

$0.50-10.61%40

TNXPTonix Pharmaceuticals Holding Corp

$5.11-1.54%40

ARCTArcturus Therapeutics Holdings Inc.

$10.87+13.94%13

VRCAVerrica Pharmaceuticals Inc.

$3.46+5.02%40

VSTMVerastem Inc.

$9.85+0.82%40

CPIXCumberland Pharmaceuticals Inc.

$4.44+3.02%13

BGMBGM Group Ltd.

$8.81-7.65%26

JANXJanux Therapeutics Inc.

$18.18+2.02%40

Held by ETFs

STOK is in 51 US ETFs. The largest of them, with STOK's weight in each:

Spot a number that looks wrong? Check it in STOK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing STOK

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.